Connect Biopharma Holdings Ltd’s stock received renewed Buy ratings from multiple analysts, with Canaccord maintaining a 12-month price target of $7.00 per share.
The San Diego-based biotech, listed on the NASDAQ under the ticker CNTB, continues to trade near recent levels, with shares last quoted at $2.45 in regular session trading. Canaccord’s target implies a potential upside of nearly 186% from current levels, aligning with the broader consensus among covering firms. Oppenheimer set an $8.00 target, while Piper Sandler and H.C. Wainwright both assigned $7.00 targets.
The analyst notes follow the company’s ongoing Phase II Seabreeze STAT program, which is evaluating rademikibart, an anti-interleukin-4-receptor alpha antibody, for the treatment of acute respiratory exacerbations in asthma and chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation. Enrollment for the Seabreeze STAT Asthma study has been completed, with topline results expected in the first week of September 2026. The Seabreeze STAT COPD study remains on track, with enrollment completion anticipated later in August 2026 and data readouts expected approximately two weeks after the asthma results.
Connect Biopharma’s financial position was also highlighted, with InvestingPro data indicating the company holds more cash than debt on its balance sheet. However, the firm continues to face significant cash burn typical of clinical-stage biotechnology companies, underscoring the importance of upcoming clinical milestones to potential funding or partnership discussions.
